VIR BIOTECHNOLOGY, I

VIR
Real-time Estimate Quote. Real-time Estimate  - 11/26 01:05:08 pm
35.385USD +10.51%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on treating and preventing serious infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. Its development pipeline consists of product candidates targeting the coronavirus disease 2019 (COVID-19), hepatitis B virus (HBV), influenza A virus and human immunodeficiency virus (HIV). Its product candidates include VIR-7831 and VIR-7832, VIR-2218, VIR-3434, VIR-2482 and VIR-111. The Company is developing VIR-7831 and VIR-7832 for the treatment of COVID-19 infection, which are severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing monoclonal antibody (mAbs). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb.VIR-1111 is a subcutaneously administered HIV T cell vaccine.

Number of employees : 327 people.
Sales per Business
2020
Contract44.5058.3%
License22.7529.8%
Grant9.1211.9%
USD in Million
Sales per region
20192020
United States8.09100%76.37100%
USD in Million
Managers
Name Title
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Herbert W. Virgin Chief Scientific Officer & Executive VP-Research
Steven Rice Chief Administrative Officer
Robert Taylor Nelsen Independent Director
Robert J. Perez Independent Director
Phillip A. Sharp Independent Director
Shareholders
Name Equities %
SB Investment Advisers (UK) Ltd. 22,616,666 17.3%
ARCH Venture Partners LLC 21,680,892 16.6%
Capital Research & Management Co. (International Investors) 8,723,656 6.68%
The Vanguard Group, Inc. 7,041,721 5.39%
GlaxoSmithKline plc 6,626,027 5.07%
George Scangos 6,520,888 4.99%
Temasek Holdings Pte Ltd. (Investment Management) 5,761,045 4.41%
Capital Research & Management Co. (World Investors) 5,009,015 3.84%
Baillie Gifford & Co. 3,899,692 2.99%
Alaska Permanent Fund Corp. 3,572,438 2.74%
Company contact information
Vir Biotechnology, Inc.
499 Illinois Street
Suite 500
5th floor
San Francisco, CA 94158

Phone : +1.415.906.4324
Web : http://www.vir.bio
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.34.43%4 191
MODERNA, INC.215.53%110 846
LONZA GROUP AG29.85%56 890
IQVIA HOLDINGS INC.46.26%50 694
SEAGEN INC.-3.22%31 671
CELLTRION, INC.-40.39%23 975
ALNYLAM PHARMACEUTICALS, INC.45.06%22 581
ICON PUBLIC LIMITED COMPANY39.50%22 292
PHARMARON BEIJING CO., LTD.57.96%22 114
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.50.20%19 051
BIO-TECHNE CORPORATION49.10%18 743
HANGZHOU TIGERMED CONSULTING CO., LTD-12.75%18 125
PPD, INC.38.37%16 621
NOVAVAX, INC.95.47%15 127
INCYTE CORPORATION-21.38%14 742
QIAGEN N.V.6.85%12 386
PRA HEALTH SCIENCES, INC.31.70%10 965
GENSCRIPT BIOTECH CORPORATION255.50%10 532
BACHEM HOLDING AG72.19%10 436
SYNEOS HEALTH, INC.45.02%10 415
UNITED THERAPEUTICS CORPORATION27.57%9 015
Brand Portfolio
» More brands of Vir Biotechnology, Inc.